Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company specializing in brain-targeted therapeutics, has provided critical updates on its Phase IIa feasibility trial for ONP-002, a potential treatment for mild traumatic brain injury (mTBI), alongside regulatory and listing developments. The company has dosed nine participants across three active clinical sites in Australia—Alfred Health, Mackay, and Royal Adelaide Hospital—signaling steady progress in the trial. This momentum is crucial as Oragenics seeks to address the significant unmet medical need in concussion care, where no FDA-approved drug currently exists.
The company also revealed that it has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package, submitted in July 2026. While Oragenics is carefully reviewing the FDA's feedback, it remains on track to submit an Investigational New Drug (IND) application by the end of 2026. This regulatory milestone is pivotal for advancing ONP-002 into U.S. clinical trials, with a Phase 2b study planned to follow the Australian Phase IIa trial. The company's proprietary intranasal delivery platform is designed to target the brain directly, potentially offering a faster and more effective treatment route for neurological conditions.
In a separate development, Oragenics disclosed receiving a deficiency letter from NYSE American on August 26, 2026, concerning stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance and intends to do so within the required timeframe. If the plan is accepted, Oragenics could maintain its listing during a cure period, subject to periodic review, with a compliance deadline of February 25, 2028. This listing status is vital for the company's access to capital markets and investor confidence.
The dual focus on clinical advancement and regulatory compliance underscores Oragenics' commitment to bringing ONP-002 to market. The drug's potential extends beyond concussion, with the intranasal platform showing promise for other neurological disorders such as Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. However, the immediate priority remains the successful completion of the Phase IIa trial and the IND submission, which are critical steps toward demonstrating safety and efficacy in a larger patient population.
For more information on Oragenics and its pipeline, visit the company's newsroom at https://nnw.fm/OGEN.
